iNOPulse for COVID-19
Purpose
This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.
Conditions
- COVID-19
- Hypoxemia
- Hypoxemic Respiratory Failure
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age 18 or above 2. Proven COVID-19 viral infection. Non-confirmed highly suspicious suspects may be enrolled. 3. Presence of radiographic findings compatible with pneumonia/pneumonitis. 4. Patients requiring at least 3 L/m oxygen via nasal canula to maintain O2 above 92%. 5. Female subjects of childbearing potential must have a negative pre-treatment pregnancy test (serum or urine). 6. Willing and able to comply with treatment schedule and study procedures.
Exclusion Criteria
- Patient with severe hypoxemia who are unable to maintain an oxygen saturation (SpO2) > 88% on a maximum supplemental oxygen of 6 L/m by nasal cannula and a non-rebreather facemask. 2. Participating in any other clinical trial for COVID-19 3. Pregnancy, or positive pregnancy test in a pre-dose examination. 4. Open tracheostomy. 5. Clinical contra-indication, as deemed by the PI or their designee. 6. Use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as intravenous lidocaine, or topical benzocaine or dapsone at screening. 7. Known history or clinical evidence of heart failure or left ventricular dysfunction (LVEF < 45%). 8. Significant hemoptysis 9. Unable to provide informed consent (proxy consent is acceptable if available) 10. Any of the following conditions at time of possible enrollment: Fulminant Liver Failure, Acute Coronary Syndrome , Renal Failure requiring dialysis, Bacteremia, Shock, Cardiac arrest, Cardiac arrhythmia requiring acute treatment, Delirium / Encephalopathy, Severe Disseminated Intravascular Coagulation, Gastrointestinal hemorrhage, Hypoglycemia, Pneumothorax, Rhabdomyolysis / Myositis, Seizures, or Acute Stroke
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental iNOpulse Treatment Group |
Participants in this group will receive iNO delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days. |
|
Active Comparator Placebo Group |
Participants in this group will receive nitrogen gas delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days |
|
Recruiting Locations
More Details
- NCT ID
- NCT04398290
- Status
- Withdrawn
- Sponsor
- Roger Alvarez